Pancreatic ductal adenocarcinoma (PDA) has an exceedingly poor prognosis with a 5-year survival of only ~6%. Unlike many other cancers, current strategies do NOT target genetic features of PDA. In part, this is because PDA is viewed as a disease that is dominated by KRAS as the oncogenic driver. As a result, therapies delivered to PDA are not targeted based on biomarkers, and chemotherapy is the mainstay for treatment. To define new means to treat PDA, we performed genetic analysis of >100 PDA cases by exome sequencing. These data revealed aberrations in multiple pathways. In particular, alterations in chromosome stability processes or cell cycle control were observed in >75% of cases. These pathways are inter-related, and would be expected to remain actionable in spite of the common deregulated KRAS signaling in PDA. Genetic alterations can lead to tumor-specific vulnerabilities that can be exploited for treatment. Here we will approach rational targeting of genetic events in PDA using two complementary efforts. First, we have defined loss/mutation of multiple pathways associated with chromosome-fidelity. These events individually are rare, but when coalesced into pathways/functional groups represent >30% of PDA patents. Our group and others have found that a specific subset of genetic events represent vulnerabilities that can be selectively targeted. Most notably germline BRCA/PALB2 mutations are the basis of the only active Phase III trial for patients with PDA. However, whether other pathways associated with chromosomal instability can be effectively targeted is unknown. These findings provide the impetus for a detailed analysis of the confluence of loss of genes involved in genome stability, resultant biological output in PDA, and selective therapeutic sensitivities. Second, therapeutic strategies can re-instate tumor suppressor activities that have been disrupted in PDA and limit proliferation to control disease. Loss of cell cycle regulatory control over CDK4/6 occurs frequently in >50% of PDA cases through loss of p16ink4a. Therefore, CDK4/6 inhibition would be expected to be exceedingly effective in PDA treatment. However, the response to CDK4/6 inhibitors is variable and cell cycle regulatory networks in PDA are particularly complex suggesting that other genetic events impinge on the efficacy of CDK4/6 inhibition. These findings provide the basis for defining the determinants of durable response to CDK4/6 inhibitors, delineating successful combination therapies, and defining the utility of such agents in disease relevant models of PDA. In total, these studies interrogate the hypothesis that therapeutic approaches targeting genetic features of PDA controlling genome stability and cell cycle control will provide critical advances to treatment.

Public Health Relevance

Pancreatic cancer has a dismal prognosis, and is a therapy recalcitrant disease for which new therapeutic approaches are needed. Here we will exploit our recent genetic analysis of the disease to determine how the genetic loss of genes controlling chromosome stability and cell cycle can be targeted for treatment.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project (R01)
Project #
Application #
Study Section
Basic Mechanisms of Cancer Therapeutics Study Section (BMCT)
Program Officer
Kondapaka, Sudhir B
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Roswell Park Cancer Institute Corp
United States
Zip Code
Knudsen, Erik S; Balaji, Uthra; Mannakee, Brian et al. (2018) Pancreatic cancer cell lines as patient-derived avatars: genetic characterisation and functional utility. Gut 67:508-520
Adams, Thomas A; Vail, Paris J; Ruiz, Amanda et al. (2018) Composite analysis of immunological and metabolic markers defines novel subtypes of triple negative breast cancer. Mod Pathol 31:288-298
Chung, Sejin; Vail, Paris J; Witkiewicz, Agnieszka K et al. (2018) Coordinately targeting cell cycle checkpoint functions in integrated models of pancreatic cancer. Clin Cancer Res :
Mannakee, Brian K; Balaji, Uthra; Witkiewicz, Agnieszka K et al. (2018) Sensitive and specific post-call filtering of genetic variants in xenograft and primary tumors. Bioinformatics 34:1713-1718
Knudsen, Erik S; Witkiewicz, Agnieszka K (2017) The Strange Case of CDK4/6 Inhibitors: Mechanisms, Resistance, and Combination Strategies. Trends Cancer 3:39-55
Knudsen, Erik S; Vail, Paris; Balaji, Uthra et al. (2017) Stratification of Pancreatic Ductal Adenocarcinoma: Combinatorial Genetic, Stromal, and Immunologic Markers. Clin Cancer Res 23:4429-4440